Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

<p>Background</p> <p>In Canada, two vaccines that have demonstrated high efficacy against infection with human papillomavirus (HPV) types −16 and −18 are available. The HPV-6/11/16/18 vaccine provides protection against genital warts (GW) while the HPV-16/18 vaccine may provide bet...

Full description

Bibliographic Details
Main Authors: Kohli Michele, Lawrence Donna, Haig Jennifer, Anonychuk Andrea, Demarteau Nadia
Format: Article
Language:English
Published: BMC 2012-10-01
Series:BMC Public Health
Subjects:
Human papillomavirus
Cervical cancer
Vaccine
Cost-effectiveness
Markov model
Canada
Online Access:http://www.biomedcentral.com/1471-2458/12/872

Internet

http://www.biomedcentral.com/1471-2458/12/872

Similar Items